SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-17-195961
Filing Date
2017-06-06
Accepted
2017-06-06 16:09:06
Documents
6
Period of Report
2017-06-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d382506d8k.htm 8-K 22890
2 EX-1.1 d382506dex11.htm EX-1.1 159278
3 EX-5.1 d382506dex51.htm EX-5.1 10646
4 EX-99.1 d382506dex991.htm EX-99.1 8444
5 GRAPHIC g382506g25o31.jpg GRAPHIC 9454
6 GRAPHIC g382506g80f39.jpg GRAPHIC 6215
  Complete submission text file 0001193125-17-195961.txt   224350
Mailing Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746
Business Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 17894244
SIC: 2834 Pharmaceutical Preparations